UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 904

Sortiert nach

The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis

The Lancet infectious diseases, 2016-11, Vol.16 (11), p.1269-1278

2016

Volltextzugriff (PDF)

Repeat Treatment With Rifaximin is Safe and Effective in Patients With Diarrhea-predominant Irritable Bowel Syndrome

Gastroenterology (New York, N.Y. 1943), 2016-12, Vol.151 (6), p.1113-1121

2016

Volltextzugriff (PDF)

A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy

The American journal of gastroenterology, 2013-09, Vol.108 (9), p.1458-1463

2013

Volltextzugriff (PDF)

Dietary and pharmacological treatment of abdominal pain in IBS

Gut, 2017-05, Vol.66 (5), p.966

2017

Volltextzugriff (PDF)

Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation

World journal of gastroenterology : WJG, 2017-07, Vol.23 (25), p.4491-4499

2017

Volltextzugriff (PDF)

Rifaximin Treatment in Hepatic Encephalopathy

The New England journal of medicine, 2010-03, Vol.362 (12), p.1071-1081

2010

Volltextzugriff (PDF)

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

The New England journal of medicine, 2011-01, Vol.364 (1), p.22-32

2011

Volltextzugriff (PDF)

Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy

PloS one, 2013-04, Vol.8 (4), p.e60042

2013

Volltextzugriff (PDF)

Rifaximin Alters Intestinal Bacteria and Prevents Stress-Induced Gut Inflammation and Visceral Hyperalgesia in Rats

Gastroenterology (New York, N.Y. 1943), 2014-02, Vol.146 (2), p.484-496.e4

2014

Volltextzugriff (PDF)

Modulation of the fecal bile acid profile by gut microbiota in cirrhosis

Journal of hepatology, 2013-05, Vol.58 (5), p.949-955

2013

Volltextzugriff (PDF)

Gut microbiota composition and diversity before, during, and two months after rifamycin-based tuberculosis preventive therapy

Scientific reports, 2023-11, Vol.13 (1), p.18933-18933, Article 18933

2023

Volltextzugriff (PDF)

Systematic review with meta‐analysis: the effects of rifaximin in hepatic encephalopathy

Alimentary pharmacology & therapeutics, 2014-07, Vol.40 (2), p.123-132

2014

Volltextzugriff (PDF)

Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy

Clinical gastroenterology and hepatology, 2014-08, Vol.12 (8), p.1390-1397.e2

2014

Volltextzugriff (PDF)

Rifamycin antibiotics and the mechanisms of their failure

Journal of antibiotics, 2021-11, Vol.74 (11), p.786-798

2021

Volltextzugriff (PDF)

Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia

Alimentary pharmacology & therapeutics, 2017-03, Vol.45 (6), p.767-776

2017

Volltextzugriff (PDF)

Rifamycins, Alone and in Combination

Cold Spring Harbor perspectives in medicine, 2016-07, Vol.6 (7), p.a027011

Rothstein, David M

2016

Volltextzugriff (PDF)

Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis

Cochrane database of systematic reviews, 2015-11 (11), p.CD001176-CD001176

2015

Volltextzugriff (PDF)

Systematic review with network meta‐analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy

Alimentary pharmacology & therapeutics, 2015-04, Vol.41 (7), p.624-635

2015

Volltextzugriff (PDF)

Linkage of gut microbiome with cognition in hepatic encephalopathy

American journal of physiology: Gastrointestinal and liver physiology, 2012-01, Vol.302 (1), p.G168-G175

2012

Volltextzugriff (PDF)

Efficacy of Rifaximin in Patients With Abdominal Bloating or Distension: A Systematic Review and Meta-analysis

Journal of clinical gastroenterology, 2024-04, Vol.58 (4), p.360

2024

Volltextzugriff (PDF)

The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review

Clinical microbiology reviews, 2023-12, Vol.36 (4), p.e0003923

DuPont, Herbert L

2023

Volltextzugriff (PDF)

Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon

Alimentary pharmacology & therapeutics, 2015-09, Vol.42 (6), p.664-684

2015

Volltextzugriff (PDF)

A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity

Alimentary pharmacology & therapeutics, 2015-01, Vol.41 (1), p.77-86

2015

Volltextzugriff (PDF)

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity

World journal of gastroenterology : WJG, 2017-12, Vol.23 (47), p.8355-8366

2017

Volltextzugriff (PDF)

A Comparative Insight on the Newly Emerging Rifamycins: Rifametane, Rifalazil, TNP-2092 and TNP-2198

Current medicinal chemistry, 2022-01, Vol.29 (16), p.2846

2022

Volltextzugriff (PDF)

1 – 25 von 904

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(746)
Mit Volltextzugriff
(546)

Publikationsform

Sprache

10 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(804)
Rifamycins - Therapeutic Use
(791)
Science & Technology
(640)
Life Sciences & Biomedicine
(627)
Female
(361)
Male
(352)
Adult
(243)
Middle Aged
(233)
Anti-Bacterial Agents - Therapeutic Use
(223)
Biological And Medical Sciences
(220)
Medical Sciences
(216)
Rifaximin
(210)
Gastroenterology & Hepatology
(206)
Pharmacology & Pharmacy
(203)
Treatment Outcome
(187)
Gastrointestinal Agents - Therapeutic Use
(183)
Pharmacology. Drug Treatments
(176)
Anti-Infective Agents - Therapeutic Use
(174)
Animals
(170)
Aged
(146)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis

Repeat Treatment With Rifaximin is Safe and Effective in Patients With Diarrhea-predominant Irritable Bowel Syndrome

A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy

Dietary and pharmacological treatment of abdominal pain in IBS

Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation

Rifaximin Treatment in Hepatic Encephalopathy

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy

Rifaximin Alters Intestinal Bacteria and Prevents Stress-Induced Gut Inflammation and Visceral Hyperalgesia in Rats

Modulation of the fecal bile acid profile by gut microbiota in cirrhosis

Gut microbiota composition and diversity before, during, and two months after rifamycin-based tuberculosis preventive therapy

Systematic review with meta‐analysis: the effects of rifaximin in hepatic encephalopathy

Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy

Rifamycin antibiotics and the mechanisms of their failure

Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia

Rifamycins, Alone and in Combination

Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis

Systematic review with network meta‐analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy

Linkage of gut microbiome with cognition in hepatic encephalopathy

Efficacy of Rifaximin in Patients With Abdominal Bloating or Distension: A Systematic Review and Meta-analysis

The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review

Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon

A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity

A Comparative Insight on the Newly Emerging Rifamycins: Rifametane, Rifalazil, TNP-2092 and TNP-2198

Suchergebnisse filtern